MedTrace Logo

The Effect of BRIZO on Lower Urinary Tract Symptoms (LUTS) Related to Benign Prostatic Hypertrophy (BPH)

NCT05227508 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-07-12

No results posted yet for this study

Summary

A randomized, placebo controlled double-blind, 12-week treatment trial in men with moderate to severe symptoms of benign prostatic hyperplasia. The trail is about to examine the effect of Brizo® on reduction of BPH related symptoms.

Conditions

  • BPH Without Urinary Obstruction and Other Lower Urinary Tract Symptoms (LUTS)

Interventions

DIETARY_SUPPLEMENT

BRIZO

A capsule containing 400 mg. SC012 (unique soy extract)

OTHER

placebo

Comprecel microcrystalline cellulose

Sponsors & Collaborators

  • Clalit Health Services

    collaborator OTHER

  • Se-cure Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Ohad Shoshani, MD · Rabin Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-31
Primary Completion
2024-01-31
Completion
2024-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05227508 on ClinicalTrials.gov